Home » Stocks » AMRS

Amyris, Inc. (AMRS)

Stock Price: $15.26 USD 0.61 (4.16%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
Pre-market: $15.02 -0.24 (-1.57%) Feb 25, 8:28 AM
Market Cap 3.84B
Revenue (ttm) 133.93M
Net Income (ttm) -352.02M
Shares Out 227.27M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $15.26
Previous Close $14.65
Change ($) 0.61
Change (%) 4.16%
Day's Open 15.62
Day's Range 14.56 - 16.06
Day's Volume 2,711,554
52-Week Range 1.40 - 18.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 3 weeks ago

Even with the market at historic highs, there are still plenty of young growth stocks that have their whole future ahead of them. The post 7 A-Rated Growth Stocks To Buy For Today And Tomorrow...

Other stocks mentioned: APPS, GRWG, JMIA, OSTK, SBE, SI
Investopedia - 4 weeks ago

These are the marijuana stocks with the best value, fastest growth, and most momentum for February 2021.

Other stocks mentioned: EGOV, GRWG, IIPR
InvestorPlace - 4 weeks ago

Some of the best cheap stocks for 2021 include chipmakers like UMC stock and pharmaceuticals in the COVID-19 vaccine race such as INO stock. The post 7 Great Cheap Stocks To Buy For Solid Grow...

Other stocks mentioned: CLNE, GNMK, HIMX, INO, STKL, UMC
PRNewsWire - 1 month ago

EMERYVILLE, Calif., Jan. 22, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer bran...

Investopedia - 1 month ago

These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and the most momentum for February.

Other stocks mentioned: APHA, CGC, CRON, EGOV, GRWG, OGI, VFF
24/7 Wall Street - 1 month ago

Over halfway through the trading day on Wednesday, and the broad markets are making a run into the afternoon.

Other stocks mentioned: TSLA, C, GS, JPM, KDP, MDB, MS, MYOV, Z, ZG
InvestorPlace - 1 month ago

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

Other stocks mentioned: CNSP, CYRN, MREO, NGD, RARE, XELA
PRNewsWire - 1 month ago

EMERYVILLE, Calif., Dec. 28, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer bran...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Amyris (AMRS) stock based on the movements in the options market lately.

Investopedia - 2 months ago

These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and the most momentum for January.

Other stocks mentioned: CGC, CRON, EGOV, GRWG, OGI, VFF
Zacks Investment Research - 2 months ago

Amyris (AMRS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

PRNewsWire - 2 months ago

EMERYVILLE, Calif., Dec. 21, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer bran...

Seeking Alpha - 2 months ago

Amyris has multiple major transactions around the corner. The political and market environment favor the company greatly.

PRNewsWire - 2 months ago

EMERYVILLE, Calif., Dec. 3, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brand...

Investopedia - 2 months ago

These are the marijuana stocks with the best value, fastest growth, and most momentum for December.

Other stocks mentioned: GRWG
Investopedia - 3 months ago

These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and the most momentum for November.

Other stocks mentioned: APHA, CGC, CRON, EGOV, GRWG, VFF
Seeking Alpha - 3 months ago

Amyris, Inc. (AMRS) CEO John Melo on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

EMERYVILLE, Calif., Oct. 30, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a t...

Business Wire - 3 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $AMRS #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $AMRS #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors

PRNewsWire - 4 months ago

EMERYVILLE, Calif., Oct. 23, 2020 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a t...

PRNewsWire - 4 months ago

SEATTLE, Oct. 20, 2020 /PRNewswire/ -- Arzeda, the Protein Design Company™, today announced that the company has entered into a joint development agreement with Amyris that leverages the compl...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $AMRS #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Amyris, Inc (“Amyris” or the “Company”...

The Motley Fool - 4 months ago

It could have been a lot worse.

Seeking Alpha - 4 months ago

Amyris' engineered yeast strains and advanced fermentation can produce an unlimited number of new products for billion-dollar markets.

Seeking Alpha - 4 months ago

Amyris bolsters balance sheet, shifting focus to cash flow, 40-50% revenue growth and earnings (we estimate $0.72 EPS in 2024).

Benzinga - 5 months ago

Amyris (NASDAQ: AMRS) shares were trading higher Tuesday after the company announced its Reb M Neutral Sweetener has received approval for use in food by Health Canada.

PRNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 14, 2020 /PRNewswire/ -- Amyris, Inc.

The Motley Fool - 5 months ago

The company has responded to a $881 million lawsuit brought against it yesterday.

Benzinga - 5 months ago

Biotech firm Amyris Inc. (NASDAQ: AMRS) is clapping back at allegations made by Lavvan Inc.

PRNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 11, 2020 /PRNewswire/ -- Amyris, Inc.

PRNewsWire - 5 months ago

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- LAVVAN, Inc.

InvestorPlace - 5 months ago

These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential ap...

Other stocks mentioned: BXRX, LIFE
PRNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 8, 2020 /PRNewswire/ -- Amyris, Inc.

Investopedia - 5 months ago

These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and best performance for September.

Other stocks mentioned: GWPH, VFF
The Motley Fool - 6 months ago

Unlocking the true value of the company's consumer portfolio might require a big, bold decision.

PRNewsWire - 6 months ago

EMERYVILLE, Calif., Aug. 14, 2020 /PRNewswire/ -- Amyris, Inc.

The Motley Fool - 6 months ago

A growing balance of deferred cost of product revenue suggests business fundamentals might be significantly worse than reported.

Seeking Alpha - 6 months ago

Amyris, Inc. (AMRS) CEO John Melo on Q2 2020 Results - Earnings Call Transcript

Investopedia - 6 months ago

These are the marijuana stocks on the nasdaq stocks with the best value, fastest growth, and best performance for August.

Other stocks mentioned: GWPH, VFF
PRNewsWire - 6 months ago

NEW YORK, July 29, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

PRNewsWire - 6 months ago

NEW YORK, July 28, 2020 /PRNewswire/ -- URGENT: SHAREHOLDER VOTE AUGUST 14, 2020 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of d...

The Motley Fool - 6 months ago

The synthetic biology pioneer announced a collaboration for its vaccine adjuvant ambitions.

Benzinga - 6 months ago

Amyris (NASDAQ: AMRS) shares are trading higher on Monday after the company signed a binding term sheet for a planned COVID-19 RNA vaccine technology program with the Infectious Disease Resear...

PRNewsWire - 6 months ago

EMERYVILLE, Calif., July 27, 2020 /PRNewswire/ -- Amyris, Inc.

InvestorPlace - 7 months ago

Smaller and speculative marijuana stocks took a beating following the initial coronavirus strike. However, they could also generate massive profitability for the risk-tolerant speculator.

Other stocks mentioned: CWBHF, HRVSF, KSHB, PLNHF, TCNNF, TPB, VFF
Business Wire - 7 months ago

LOS ANGELES--(BUSINESS WIRE)---- $AMRS #AMRS--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amyris, Inc.

Business Wire - 7 months ago

LOS ANGELES--(BUSINESS WIRE)---- $AMRS #AMRS--INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims Against Amyris, Inc.

Forbes - 7 months ago

Markets are down today, pretty much from the get-go. As investors become increasingly concerned with the worsening coronavirus cases, it's become clear that a sell-off is imminent.

Other stocks mentioned: BKYI, COCP, MRAM, OSBC
Zacks Investment Research - 7 months ago

Investors need to pay close attention to Amyris (AMRS) stock based on the movements in the options market lately.

About AMRS

Amyris, a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette... [Read more...]

Industry
Specialty Chemicals
IPO Date
Sep 28, 2010
CEO
John Melo
Employees
561
Stock Exchange
NASDAQ
Ticker Symbol
AMRS
Full Company Profile

Financial Performance

In 2019, Amyris's revenue was $152.56 million, an increase of 139.85% compared to the previous year's $63.60 million. Losses were -$242.77 million, 5.44% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Amyris stock is "Strong Buy." The 12-month stock price forecast is 12.00, which is a decrease of -21.36% from the latest price.

Price Target
$12.00
(-21.36% downside)
Analyst Consensus: Strong Buy